Biopharma’s stock market winners of 2021 revealed

Covid’s ability to infect share prices remained intact last year: the pandemic spurred some of the best performances among biopharma stocks, but was also responsible for several fallers. Indeed, a few names appeared on the other side of the leader boards compared with this time last year.